Journal article · 2023 · Open access
Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy
BMJ Open, 13(9), e071500 · Published 1 September 2023 · DOI 10.1136/bmjopen-2022-071500
In brief
“Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy” is a 2023 journal article by Ouki Kuniyoshi and 11 co-authors, published in BMJ Open. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at BMJ Open.
- Citations
- 0
- References
- 27
- Authors
- 12
Abstract
INTRODUCTION: Symptom-related adverse events associated with perioperative chemotherapy in patients with breast cancer include short-term adverse events such as nausea and vomiting. However, changes in the severity and duration of prolonged symptom-related adverse events have not been fully investigated. We present a protocol of a study that aims to clarify the prevalence of symptom-related adverse events in patients with breast cancer 1 year after neoadjuvant or adjuvant chemotherapy using an electronic patient-reported outcomes (ePRO) system. METHODS AND ANALYSIS: This multicentre prospective observational cohort study will include patients with breast cancer who have received preoperative or postoperative adjuvant chemotherapy. The final injection date of the cytotoxic agent will be the study initiation date. Patients will report every 2 weeks from the initiation date to 12 weeks and every 4 weeks from 12 weeks to 1 year, and they can enter this information into the ePRO system from anywhere. The primary outcome will be the prevalence of symptom-related adverse events according to the ePRO system 1 year after the date of the last injection of the cytotoxic drug used in neoadjuvant or adjuvant chemotherapy for breast cancer. To increase multi-institutional enrolment, two cohorts will be included. Cohort 1 will comprise patients with acquisition of baseline patient information regarding preoperative chemotherapy and presurgery characteristics. Cohort 2 will comprise patients without acquisition of baseline patient information. The target sample size is ≥250 per year. ETHICS AND DISSEMINATION: The study protocol has been approved by the ethics committee at each participating institution. The results will be presented at major national and international conferences and submitted to peer-reviewed journals. TRIAL STATUS: Registration was started in October 2021. By August 2022, a total of 132 participants were enrolled. Follow-up will be continued through December 2024. TRIAL REGISTRATION NUMBER: UMIN000045422.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kuniyoshi, O., Sano, M., Nakano, Y., Kawaguchi, T., Hatakeyama, T., Tsuchiya, Y., Inada, Y., Harada, T., Kurosaki, M., Mashiko, T., Miyaji, T., & Yamaguchi, T. (2023). Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy. BMJ Open, 13(9), e071500. https://doi.org/10.1136/bmjopen-2022-071500
MLA 9
Kuniyoshi, Ouki, et al. “Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy.” BMJ Open, vol. 13, no. 9, 2023, p. e071500. https://doi.org/10.1136/bmjopen-2022-071500.
Chicago
Kuniyoshi, Ouki, Motohiko Sano, Yasuhiro Nakano, Takashi Kawaguchi, Tomoki Hatakeyama, Yusuke Tsuchiya, Yusuke Inada, et al. 2023. “Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy.” BMJ Open 13 (9): e071500. https://doi.org/10.1136/bmjopen-2022-071500.
Harvard
Kuniyoshi, O. et al. (2023) ‘Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy’, BMJ Open, 13(9), p. e071500. doi:10.1136/bmjopen-2022-071500.
IEEE
O. Kuniyoshi et al., “Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy,” BMJ Open, vol. 13, no. 9, p. e071500, 2023, doi: 10.1136/bmjopen-2022-071500.
BibTeX
@article{kuniyoshi2023protocol,
title = {{Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy}},
author = {Kuniyoshi, Ouki and Sano, Motohiko and Nakano, Yasuhiro and Kawaguchi, Takashi and Hatakeyama, Tomoki and Tsuchiya, Yusuke and Inada, Yusuke and Harada, Tomohiko and Kurosaki, Miyuki and Mashiko, Tomoe and Miyaji, Tempei and Yamaguchi, Takuhiro},
journal = {BMJ Open},
year = {2023},
volume = {13},
number = {9},
pages = {e071500},
doi = {10.1136/bmjopen-2022-071500},
url = {https://doi.org/10.1136/bmjopen-2022-071500}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer survivorship and care
- breast cancer
- adjuvant chemotherapy
- neoadjuvant chemotherapy
- electronic patient-reported outcomes
- late effects
- nausea and vomiting
- chemotherapy toxicity
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Kuniyoshi, O., Sano, M., Nakano, Y., Kawaguchi, T., Hatakeyama, T., Tsuchiya, Y., Inada, Y., Harada, T., Kurosaki, M., Mashiko, T., Miyaji, T., & Yamaguchi, T. (2023). Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy. BMJ Open, 13(9), e071500. https://doi.org/10.1136/bmjopen-2022-071500
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at BMJ Open: sign in and open the PDF from this page.
Who wrote this paper?
Ouki Kuniyoshi, Motohiko Sano, Yasuhiro Nakano, Takashi Kawaguchi, Tomoki Hatakeyama, Yusuke Tsuchiya, Yusuke Inada, Tomohiko Harada, Miyuki Kurosaki, Tomoe Mashiko, Tempei Miyaji, Takuhiro Yamaguchi.
What is the DOI of this paper?
10.1136/bmjopen-2022-071500, permanently at https://doi.org/10.1136/bmjopen-2022-071500. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.